Table 3.

Frequency of Copy Number Amplifications and Deletions Present in All 23 Synchronous Tumors Samples from aCGH Data.

Copy Number Amplifications	Copy Number Deletions
1p (39.1%), 1q (52.2%), 2q (21.7%), 3p (4.4%), 4q (30.4%), 5q (4.3%), 6p (4.3%), 6q (8.7%), 7p (17.4%), 7q (21.7%), 8q (21.7%), 9p (8.7%), 9q (17.4%), 10q (8.7%), 11p (21.8%), 11q (21.8%), 12p (4.4%), 12q (21.8%), 13q (8.7%), 14q (13.0%), 16p (4.4%), 17q (4.4%), 18p (8.7%), 18q (8.7%), 20q (4.4%), 21q (8.7%), 22q (4.4%), Xp (17.4%)	1p (39.1%), 1q (53.2%), 2q (21.8%), 3p (4.4%), 4q (30.4%), 5p (4.4%), 5q (4.4.%), 6p (4.4%), 6q (8.7%), 7p (17.4%), 7p (17.4%), 7q (17.4%), 8q (13.0%), 10q (8.7%), 11p (30.4%), 11q (13.0%), 12p (8.7%), 17q (13.0%), 18p (13.0%), 18q (8.7%), Xq (26.1%)

The SAM method was used to determine statistically significant recurrent amplified and deleted regions associated with synchronous tumors. Copy number alterations were categorized based on type (amplification or deletion) and further grouped based on the chromosomal arm where the alterations are present.